Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

HubRx make key appointments as it prepares to launch UK's first automated pharmacy

Ahead of the launch of UK’s first state-of-the-art automated hub for independent community pharmacists, HubRx has announced the appointment of Karl Wooldridge as operations director and Matthew Tollefson as chief financial officer.

Karl brings more than 14 years of sector experience to his new role with HubRx. Having begun his career as an independent community pharmacist, Karl has gone on to hold key roles within pharmacy automation, including managing Phoenix Medical Supplies’ offsite dispensing service.


Commenting on his appointment, Karl said: “I’m delighted to have joined the team. The pandemic has further highlighted the important role pharmacists can play in keeping the nation healthy, not least in the delivery of the latest vaccination programme. The focus is now on pharmacists offering more clinical services, but to be able to achieve that the dispensing burden needs to be reduced.

“HubRx is pioneering, our approach will transform community pharmacy. We’re investing in cutting-edge technology to create an automated dispensing hub that will create capacity for pharmacists, allow them to grow and expand their skills.”

Matthew joins from Leeds-based corporate finance firm, Sentio Partners having also held positions with Mazars and Ernst & Young.

Matthew adds: “Joining HubRx was an offer I could not pass up. The pedigree and health tech expertise driving the business is second to none, it’s a true example of disruption to make a positive change to the lives of pharmacists and patients.

“Groups have been able to benefit from using a hub and spoke model for years. We’re creating HubRx to level the playing field.”

HubRx will be able to free up prescription dispensary time for upwards of 200 independent community pharmacies through a unique hub and spoke model from a state-of-the-art 40,000 sq. ft. fully automated facility which will be capable of dispensing up to 12 million healthcare items per year.

Daniel Lee, HubRx CEO adds: “We’re thrilled to welcome both Karl and Matthew to the team. Karl is well known within the sector and has unrivalled expertise in pharmacy automation, which combined with his experience as an independent community pharmacist provides him with a unique perspective that will not only benefit HubRX, but also our customers.”

Founded by CEO Daniel Lee, formerly of Pharmacy2U, and Chairman Sean Riddell formerly of EMIS Group, HubRx team has more that 20 years of experience in digital healthcare and centralised automated dispensing.

More For You

NHS app to boost clinical trials

The focus is on encouraging people from underrepresented groups, including minorities from African and Asian heritage, to sign up for clinical trials.

iStock

Government to use NHS app to boost clinical trials

The government’s 10-Year Health Plan is expected to provide a fillip to clinical trials, and it plans to make use of the NHS App to encourage people to sign up as participants.

People will be able to sign up for the NIHR Be Part of Research service (bepartofresearch.uk) on the NHS App for the trials best suited to their interests and needs.

Keep ReadingShow less
US pharma bets big on China to snap up potential blockbuster drugs

Through June, US drugmakers have signed 14 deals potentially worth $18.3 billion to license drugs from China-based companies

US pharma bets big on China to snap up potential blockbuster drugs

US drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data, betting they can turn upfront payments of as little as $80 million into multibillion-dollar treatments.

Through June, US drugmakers have signed 14 deals potentially worth $18.3 billion to license drugs from China-based companies. That compares with just two such deals in the year-earlier period, according to data from GlobalData provided exclusively to Reuters.

Keep ReadingShow less
Alliance Healthcare team raises thousands with charity bike ride to Paris

The Alliance Healthcare team

Alliance Healthcare team raises thousands with charity bike ride to Paris

Eight Alliance Healthcare team members raised over £55,000 for Theodora Children’s Charity by cycling from Surrey to Paris.

From June 13th-15th, the team took on the gruelling 300 mile cross-border Tour D’Alliance 2025 challenge and raised vital funds to support children who may be living with serious health challenges through Theodora Children’s Charity’s Giggle Doctor programme.

Keep ReadingShow less
Over four million flu vaccines across England in the 2024/25 winter flu season.

Over four million flu vaccines across England in the 2024/25 winter flu season.

CCA release

Community pharmacy administered over four million flu vaccines

Community pharmacy administered over four million flu vaccines across England in the 2024/25 winter flu season, the highest outside of the pandemic, according to the Company Chemists’ Association.

This is nearly 10 per cent higher than the number of flu vaccines administered in 2023/24.

Keep ReadingShow less
Chemotherapy-free leukaemia treatment

The trial found that a combination of two cancer drugs, ibrutinib and venetoclax, could perform better than chemotherapy among patients with chronic lymphocytic leukaemia.

iStock

Chemotherapy-free leukaemia treatment shows promise during trial

In a breakthrough in leukaemia research, scientists in the UK have tested a chemotherapy-free approach, involving a combination of targeted drugs, which may offer better outcomes.

The new treatment could radically change the way chronic lymphocytic leukaemia (CLL), the most common form of leukaemia in adults, is treated.

Keep ReadingShow less